{"product_id":"ovagen-20mg-vial","title":"Ovagen 20mg vial","description":"\u003cp data-start=\"92\" data-end=\"394\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                            \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"92\" data-end=\"394\"\u003e\u003cstrong data-start=\"92\" data-end=\"103\"\u003eOvagen®\u003c\/strong\u003e is marketed in the “peptide bioregulator” ecosystem as a \u003cstrong data-start=\"161\" data-end=\"206\"\u003eliver and gastrointestinal tract–directed\u003c\/strong\u003e peptide product. In many research\/vendor descriptions, “Ovagen” is presented as an \u003cstrong data-start=\"290\" data-end=\"315\"\u003eultrashort tripeptide\u003c\/strong\u003e with the sequence \u003cstrong data-start=\"334\" data-end=\"355\"\u003eGlu–Asp–Leu (EDL)\u003c\/strong\u003e. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"396\" data-end=\"626\"\u003eIn product-line brochures, Ovagen is also described as a \u003cstrong data-start=\"453\" data-end=\"472\"\u003epeptide complex\u003c\/strong\u003e (often labeled \u003cstrong data-start=\"488\" data-end=\"496\"\u003eAC-3\u003c\/strong\u003e, “liver”), i.e., a \u003cem data-start=\"516\" data-end=\"525\"\u003emixture\u003c\/em\u003e of short peptides intended to mimic natural peptide fractions. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"628\" data-end=\"936\"\u003e\u003cstrong data-start=\"628\" data-end=\"670\"\u003ePractical identity caveat (important):\u003c\/strong\u003e depending on the supplier, “Ovagen” may mean \u003cstrong data-start=\"716\" data-end=\"723\"\u003e(a)\u003c\/strong\u003e the defined \u003cstrong data-start=\"736\" data-end=\"754\"\u003eEDL tripeptide\u003c\/strong\u003e, or \u003cstrong data-start=\"759\" data-end=\"766\"\u003e(b)\u003c\/strong\u003e a branded \u003cstrong data-start=\"777\" data-end=\"801\"\u003eAC-3 peptide complex\u003c\/strong\u003e. For scientific writing, you should explicitly state which one you mean and require \u003cstrong data-start=\"886\" data-end=\"901\"\u003eCOA\/MS\/HPLC\u003c\/strong\u003e if discussing a specific molecule.\u003c\/p\u003e\n\u003chr data-start=\"938\" data-end=\"941\"\u003e\n\u003ch3 data-start=\"943\" data-end=\"1006\"\u003e2) Biological rationale: why a liver\/GI ultrashort peptide?\u003c\/h3\u003e\n\u003cp data-start=\"1007\" data-end=\"1302\"\u003eThe \u003cstrong data-start=\"1011\" data-end=\"1038\"\u003ebioregulator hypothesis\u003c\/strong\u003e (Khavinson-style) proposes that \u003cstrong data-start=\"1071\" data-end=\"1098\"\u003e2–4 amino-acid peptides\u003c\/strong\u003e can enter cells and influence \u003cstrong data-start=\"1129\" data-end=\"1148\"\u003egene expression\u003c\/strong\u003e programs in a tissue-biased manner, potentially via interactions with DNA\/chromatin and transcriptional regulation. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"1304\" data-end=\"1411\"\u003eFor an acidic tripeptide like \u003cstrong data-start=\"1334\" data-end=\"1362\"\u003eEDL (Glu\/Asp-containing)\u003c\/strong\u003e, the gene-regulation framework often emphasizes:\u003c\/p\u003e\n\u003cul data-start=\"1412\" data-end=\"1670\"\u003e\n\u003cli data-start=\"1412\" data-end=\"1536\"\u003e\n\u003cp data-start=\"1414\" data-end=\"1536\"\u003ephysicochemical interactions of charged residues with nucleic acids (as a conceptual basis for DNA\/chromatin effects), and\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1537\" data-end=\"1670\"\u003e\n\u003cp data-start=\"1539\" data-end=\"1670\"\u003edownstream shifts in transcription programs relevant to cellular stress responses and repair. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"1672\" data-end=\"1675\"\u003e\n\u003ch2 data-start=\"1677\" data-end=\"1721\"\u003e3) Proposed molecular mechanism of action\u003c\/h2\u003e\n\u003ch3 data-start=\"1723\" data-end=\"1797\"\u003e3.1 “Pharmacodynamics” framing (non-receptor, gene-program modulation)\u003c\/h3\u003e\n\u003cp data-start=\"1798\" data-end=\"1975\"\u003eUnlike GLP-1 agonists or monoclonal antibodies, Ovagen\/EDL is not framed as a ligand for a canonical receptor with a well-mapped signaling cascade. It is typically described as:\u003c\/p\u003e\n\u003cul data-start=\"1976\" data-end=\"2214\"\u003e\n\u003cli data-start=\"1976\" data-end=\"2063\"\u003e\n\u003cp data-start=\"1978\" data-end=\"2063\"\u003ecapable of \u003cstrong data-start=\"1989\" data-end=\"2021\"\u003ecell and nuclear penetration\u003c\/strong\u003e (general claim across bioregulators), and\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2064\" data-end=\"2214\"\u003e\n\u003cp data-start=\"2066\" data-end=\"2214\"\u003einfluencing \u003cstrong data-start=\"2078\" data-end=\"2104\"\u003etranscription patterns\u003c\/strong\u003e that govern hepatocellular metabolism, antioxidant defense, and repair. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"2216\" data-end=\"2259\"\u003e3.2 Downstream biology (hypothesis map)\u003c\/h3\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"2260\" data-end=\"2796\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"2260\" data-end=\"2336\"\u003e\n\u003ctr data-start=\"2260\" data-end=\"2336\"\u003e\n\u003cth data-start=\"2260\" data-end=\"2269\" data-col-size=\"sm\"\u003eDOMAIN\u003c\/th\u003e\n\u003cth data-start=\"2269\" data-end=\"2290\" data-col-size=\"sm\"\u003eEXPECTED DIRECTION\u003c\/th\u003e\n\u003cth data-start=\"2290\" data-end=\"2336\" data-col-size=\"md\"\u003eMECHANISTIC RATIONALE (as commonly framed)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"2352\" data-end=\"2796\"\u003e\n\u003ctr data-start=\"2352\" data-end=\"2484\"\u003e\n\u003ctd data-start=\"2352\" data-end=\"2387\" data-col-size=\"sm\"\u003eHepatocellular stress resilience\u003c\/td\u003e\n\u003ctd data-start=\"2387\" data-end=\"2391\" data-col-size=\"sm\"\u003e↑\u003c\/td\u003e\n\u003ctd data-start=\"2391\" data-end=\"2484\" data-col-size=\"md\"\u003eproposed antioxidant\/repair gene program modulation \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2485\" data-end=\"2650\"\u003e\n\u003ctd data-start=\"2485\" data-end=\"2526\" data-col-size=\"sm\"\u003eDetoxification \u0026amp; metabolic homeostasis\u003c\/td\u003e\n\u003ctd data-start=\"2526\" data-end=\"2530\" data-col-size=\"sm\"\u003e↑\u003c\/td\u003e\n\u003ctd data-start=\"2530\" data-end=\"2650\" data-col-size=\"md\"\u003e“liver-targeted” transcriptional normalization concept (bioregulator paradigm) \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2651\" data-end=\"2796\"\u003e\n\u003ctd data-start=\"2651\" data-end=\"2675\" data-col-size=\"sm\"\u003eGI–liver axis support\u003c\/td\u003e\n\u003ctd data-start=\"2675\" data-end=\"2695\" data-col-size=\"sm\"\u003econtext-dependent\u003c\/td\u003e\n\u003ctd data-start=\"2695\" data-end=\"2796\" data-col-size=\"md\"\u003epositioned as liver + GI tract support in branded materials \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp data-start=\"2798\" data-end=\"2930\"\u003e\u003cstrong data-start=\"2798\" data-end=\"2828\"\u003eInterpretation constraint:\u003c\/strong\u003e these are \u003cem data-start=\"2839\" data-end=\"2886\"\u003emechanistic hypotheses and positioning claims\u003c\/em\u003e, not clinically proven therapeutic effects.\u003c\/p\u003e\n\u003chr data-start=\"2932\" data-end=\"2935\"\u003e\n\u003ch2 data-start=\"2937\" data-end=\"3015\"\u003e4) Pharmacokinetics and delivery constraints (what can be said responsibly)\u003c\/h2\u003e\n\u003cp data-start=\"3016\" data-end=\"3118\"\u003eThere is \u003cstrong data-start=\"3025\" data-end=\"3053\"\u003eno FDA\/EMA drug label PK\u003c\/strong\u003e for Ovagen (EDL or AC-3). Key realities for ultrashort peptides:\u003c\/p\u003e\n\u003cul data-start=\"3119\" data-end=\"3538\"\u003e\n\u003cli data-start=\"3119\" data-end=\"3209\"\u003e\n\u003cp data-start=\"3121\" data-end=\"3209\"\u003e\u003cstrong data-start=\"3121\" data-end=\"3152\"\u003eRapid enzymatic degradation\u003c\/strong\u003e is typical without stabilization\/formulation strategies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3210\" data-end=\"3377\"\u003e\n\u003cp data-start=\"3212\" data-end=\"3377\"\u003eExposure and effect are \u003cstrong data-start=\"3236\" data-end=\"3267\"\u003eroute\/formulation dependent\u003c\/strong\u003e (capsule vs sublingual drops vs injectable “research peptide” are not interchangeable in any rigorous sense).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3378\" data-end=\"3538\"\u003e\n\u003cp data-start=\"3380\" data-end=\"3538\"\u003eProduct brochures describe oral\/sublingual “bioregulator” formats, but these do not substitute for formal PK\/PD studies. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"3540\" data-end=\"3543\"\u003e\n\u003ch2 data-start=\"3545\" data-end=\"3589\"\u003e5) Evidence base: preclinical vs clinical\u003c\/h2\u003e\n\u003ch3 data-start=\"3591\" data-end=\"3654\"\u003e5.1 Mechanistic \/ preclinical (stronger, but still limited)\u003c\/h3\u003e\n\u003cp data-start=\"3655\" data-end=\"3937\"\u003eThe strongest defensible foundation is the \u003cstrong data-start=\"3698\" data-end=\"3749\"\u003ebroader gene-expression bioregulator literature\u003c\/strong\u003e, which discusses ultrashort peptide–DNA interactions and transcriptional modulation mechanisms (framework-level, not Ovagen-specific clinical proof). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"3939\" data-end=\"4166\"\u003eSome sources also describe Ovagen as being used in research on \u003cstrong data-start=\"4002\" data-end=\"4051\"\u003ehepatocellular repair and antioxidant defense\u003c\/strong\u003e (again, positioning rather than a standardized clinical endpoint dataset). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-start=\"4168\" data-end=\"4249\"\u003e5.2 Human clinical evidence (weaker \/ not drug-grade from accessible sources)\u003c\/h3\u003e\n\u003cp data-start=\"4250\" data-end=\"4600\"\u003eBranded brochures and commercial summaries claim benefits such as “normalization” of liver\/GI function and support under stress\/aging, but these materials generally do \u003cstrong data-start=\"4418\" data-end=\"4425\"\u003enot\u003c\/strong\u003e present full RCT-grade methods and outcomes (randomization, blinding, prespecified endpoints, effect sizes, adverse event accounting). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"4602\" data-end=\"4605\"\u003e\n\u003ch2 data-start=\"4607\" data-end=\"4657\"\u003e6) Safety and tolerability (risk-based framing)\u003c\/h2\u003e\n\u003cp data-start=\"4658\" data-end=\"4790\"\u003e\u003cstrong data-start=\"4658\" data-end=\"4687\"\u003eHigh-certainty statement:\u003c\/strong\u003e Ovagen (as sold in the bioregulator\/research market) does not carry a drug-label–grade safety profile.\u003c\/p\u003e\n\u003cp data-start=\"4792\" data-end=\"4817\"\u003eMain uncertainty drivers:\u003c\/p\u003e\n\u003cul data-start=\"4818\" data-end=\"5198\"\u003e\n\u003cli data-start=\"4818\" data-end=\"4878\"\u003e\n\u003cp data-start=\"4820\" data-end=\"4878\"\u003e\u003cstrong data-start=\"4820\" data-end=\"4844\"\u003eIdentity variability\u003c\/strong\u003e (EDL tripeptide vs AC-3 complex).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4879\" data-end=\"5009\"\u003e\n\u003cp data-start=\"4881\" data-end=\"5009\"\u003e\u003cstrong data-start=\"4881\" data-end=\"4921\"\u003ePurity\/contamination\/sterility risks\u003c\/strong\u003e depending on supply chain and intended route (especially for “research peptide” vials).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5010\" data-end=\"5198\"\u003e\n\u003cp data-start=\"5012\" data-end=\"5198\"\u003e\u003cstrong data-start=\"5012\" data-end=\"5050\"\u003eOff-target transcriptional effects\u003c\/strong\u003e are theoretically possible for agents proposed to modulate gene expression—this increases the importance of controlled trials before strong claims.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"5200\" data-end=\"5203\"\u003e\n\u003ch2 data-start=\"5205\" data-end=\"5231\"\u003e7) Regulatory landscape\u003c\/h2\u003e\n\u003cp data-start=\"5232\" data-end=\"5441\"\u003eOvagen is typically marketed as a \u003cstrong data-start=\"5266\" data-end=\"5298\"\u003ebioregulator peptide complex\u003c\/strong\u003e or \u003cstrong data-start=\"5302\" data-end=\"5322\"\u003eresearch peptide\u003c\/strong\u003e, and is \u003cstrong data-start=\"5331\" data-end=\"5370\"\u003enot an FDA\/EMA-approved therapeutic\u003c\/strong\u003e with standardized indications. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"5443\" data-end=\"5446\"\u003e\n\u003ch2 data-start=\"5448\" data-end=\"5513\"\u003e8) Future directions (what would make Ovagen “clinical-grade”)\u003c\/h2\u003e\n\u003cp data-start=\"5514\" data-end=\"5609\"\u003eTo validate Ovagen scientifically as a modern therapeutic concept, the decisive steps would be:\u003c\/p\u003e\n\u003col data-start=\"5610\" data-end=\"6140\"\u003e\n\u003cli data-start=\"5610\" data-end=\"5723\"\u003e\n\u003cp data-start=\"5613\" data-end=\"5723\"\u003e\u003cstrong data-start=\"5613\" data-end=\"5637\"\u003eMolecule definition:\u003c\/strong\u003e separate “EDL” vs “AC-3 complex” with exact composition, stability, impurity profile.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5724\" data-end=\"5880\"\u003e\n\u003cp data-start=\"5727\" data-end=\"5880\"\u003e\u003cstrong data-start=\"5727\" data-end=\"5752\"\u003eHuman PK\/PD bridging:\u003c\/strong\u003e demonstrate systemic exposure (or local mucosal uptake) and target-engagement biomarkers (liver transcriptomic\/stress markers).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5881\" data-end=\"6140\"\u003e\n\u003cp data-start=\"5884\" data-end=\"6140\"\u003e\u003cstrong data-start=\"5884\" data-end=\"5906\"\u003eControlled trials:\u003c\/strong\u003e well-defined populations (e.g., NAFLD risk, drug-induced liver injury prevention contexts, etc.), with validated endpoints (ALT\/AST trajectories, imaging biomarkers where relevant, symptom\/QoL measures), and robust safety monitoring.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003chr data-start=\"6142\" data-end=\"6145\"\u003e\n\u003ch2 data-start=\"6147\" data-end=\"6189\"\u003eSelected references (most load-bearing)\u003c\/h2\u003e\n\u003cul data-start=\"6190\" data-end=\"6721\"\u003e\n\u003cli data-start=\"6190\" data-end=\"6306\"\u003e\n\u003cp data-start=\"6192\" data-end=\"6306\"\u003eOvagen positioned as liver\/GI bioregulator; AC-3 complex (brochure PDF): \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6307\" data-end=\"6431\"\u003e\n\u003cp data-start=\"6309\" data-end=\"6431\"\u003eOvagen described as \u003cstrong data-start=\"6329\" data-end=\"6350\"\u003eEDL (Glu–Asp–Leu)\u003c\/strong\u003e in multiple research\/vendor summaries: \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6432\" data-end=\"6581\"\u003e\n\u003cp data-start=\"6434\" data-end=\"6581\"\u003eSystematic review providing the broader \u003cstrong data-start=\"6474\" data-end=\"6528\"\u003eultrashort peptide gene-expression\/DNA interaction\u003c\/strong\u003e framework: \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6582\" data-end=\"6721\"\u003e\n\u003cp data-start=\"6584\" data-end=\"6721\"\u003eExample vendor description emphasizing hepatocellular repair\/antioxidant gene modulation framing:\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684841714002,"sku":null,"price":55.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/Ovagen_20mg.png?v=1770834798","url":"https:\/\/sciencepeptideslab.com\/products\/ovagen-20mg-vial","provider":"Science Peptides Lab","version":"1.0","type":"link"}